The DOI matches its Crossref record; 228 of the 230 references it cites were found in a registry or an index.
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Open accessAbstract
Post-transplant diabetes mellitus (PTDM) is a frequent consequence of solid organ transplantation. PTDM has been associated with greater mortality and increased infections in different transplant groups using different diagnostic criteria. An international consensus panel recommended a consistent set of guidelines in 2003 based on American Diabetes Association glucose criteria but did not exclude the immediate post-transplant hospitalization when many patients receive large doses of corticosteroids. Greater glucose monitoring during all hospitalizations has revealed significant glucose intolerance in the majority of recipients immediately after transplant. As a result, the international consensus panel reviewed its earlier guidelines and recommended delaying screening and diagnosis of PTDM until the recipient is on stable doses of immunosuppression after discharge from initial transplant hospitalization. The group cautioned that whereas hemoglobin A1C has been adopted as a diagnostic criterion by many, it is not reliable as the sole diabetes screening method during the first year after transplant. Risk factors for PTDM include many of the immunosuppressant medications themselves as well as those for type 2 diabetes. The provider managing diabetes and associated dyslipidemia and hypertension after transplant must be careful of the greater risk for drug-drug interactions and infections with immunosuppressant medications. Treatment goals and therapies must consider the greater risk for fluctuating and reduced kidney function, which can cause hypoglycemia. Research is actively focused on strategies to prevent PTDM, but until strategies are found, it is imperative that immunosuppression regimens are chosen based on their evidence to prolong graft survival, not to avoid PTDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its unquestionable impact as a signi fi cant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its impact as a significant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,359
Cited by
Items 301–328 of 328
Liu, Y., Cao, Z., Wen, P., Gao, R., Qiu, C., Wang, R., Shi, B., An, W., Shi, W., Xia, Y., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7682951/v1
Allen, R. B., Stevenson, E., Goley, A. L., Alexander, B., Ma, J., Raiger, T. B., Chandran, M. M., & Szempruch, K. R. (2025) · Transplantology · doi:10.3390/transplantology6040030
Struja, T., Nitritz, N., Alexander, I., Kupferschmid, K., Hafner, J. F., Spagnuolo, C. C., Schüetz, P., Mueller, B., & Blum, C. A. (2024) · Figshare · doi:10.6084/m9.figshare.25097345
Yeh, H., Cc, L., Li, Y.-R., Yen, C.-L., Lee, C.-C., Chen, J.-S., Chen, K.-H., Tian, Y.-C., Liu, P.-H., & Hsiao, C.-C. (2020) · Figshare · doi:10.6084/m9.figshare.12211415
Lin, H., Yan, J., Yuan, L., Qi, B., Zhang, Z., Zhang, W., Ma, A., & 丁福万 (2021) · Figshare · doi:10.6084/m9.figshare.16909954
Mortality and cardiovascular events in new onset diabetes mellitus after renal transplantation
Lima, J. J. G. D., Gowdak, L. H. W., Reusing, J. O., David-Neto, E., & Bortolotto, L. A. (2025) · Canadian Journal of General Internal Medicine · doi:10.3138/cjgim.2025.0004
Long-Term Complications of Immunosuppression
Mehtani, R., Agarwal, J., & Saigal, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-2624-6_38
Hosseini, M. S., Hajimiri, S. H., Dashti‐Khavidaki, S., Nasiri‐Toosi, M., Moghadamnia, M., Talebian, M., & Kebriaeezadeh, A. (2026) · Research Square · doi:10.21203/rs.3.rs-8712266/v1
Mei, K., Casabar, M., Mukuba, D., Byrne, C., & Chowdhury, T. A. (2026) · Diabetic Medicine · doi:10.1111/dme.70248
Kidney Transplant Outcomes in Patients with and without Type II Diabetes Mellitus
Lindeman, J. H. N., Ploeg, R. J., Sharples, E. J., Alwayn, I. P. J., Bemelman, F. J., Berger, S. P., Christiaans, M. H. L., Konijn, C., de Vries, A. P. J., van de Wetering, J., et al. (2026) · Cardiorenal Medicine · doi:10.1159/000551839
Ignatova, Y. S., Shaputko, D. N., Борзалиевна, П. Т., & Barbarash, O. L. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-6464
Dhanasekaran, M., Ataallah, B., Shakil, J., & Patham, B. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.04.006
Hyperglycemia following pancreas transplantation: Rethinking graft function and metabolic control
Singh, N., Parajuli, S., Rao, S., Alhamad, T., Niederhaus, S. V., Nieves‐Rivera, F., Diab, A., Stumpf, M. M., Albritton, M., Singh, A., et al. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.05.714
Chen, R., Guo, Z., Li, G. H., Fang, J., Wu, J., Liu, L., & Chen, Z. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07585-6
“…varies substantially across cohorts and diagnostic strategies, with contemporary estimates commonly in the range of approximately 15%–30% in the first post‑transplant year, and higher rates observed in higher‑risk populations and when systematic oral glucose tolerance testing (OGTT) is used [1, 2].”
InfluentialCrepaldi, M. C., Vedovato, M., Morieri, M. L., Basso, G., Stefanelli, L. F., Alessi, M., Fioretto, P., & Fadini, G. P. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01885-1
“In addition to pre-existing metabolic risk factors, transplant recipients are exposed to diabetogenic immunosuppressive agents (especially calcineurin inhibitors, mTOR inhibitors, and glucocorticoids) which impair β -cell function and exacerbate insulin resistance [3, 7].”
InfluentialKhury, F., Saba, B. V., Shanaa, J., Rozell, J. C., Aggarwal, V. K., & Schwarzkopf, R. M. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-026-04740-y
“Moreover, these agents can exacerbate or induce systemic conditions such as osteoporosis, renal dysfunction, and diabetes mellitus, further complicating perioperative risk stratification and management [ 22, 23].”
Liu, J.-R., Zhao, L., Niu, Q., Cai, J.-Z., & Liu, H.-Y. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.121285
Siam, S., Boeckel, G. R., Hasan, C., Pavenstädt, H., Budde, K., & Reuter, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1867698
Park, J., Park, J., Lee, H., Lee, J., Jo, Y. S., David, D., Newgard, C. B., Thomas, G., & Kozma, S. C. (2026) · Toxicological Research · doi:10.1007/s43188-026-00363-x
Soleimani, S., Hasnijeh, F. K., Vasheghani, M., Naghashzadeh, F., Ahmadi, Z. H., کاشانی, ب. ش., Nouri, F., Alizadeh, N., & Shafaghi, S. (2026) · Intern J Endocrinol Metab · doi:10.5812/ijem-168325
Hyodeoxycholic acid ameliorates tacrolimus-induced diabetes by modulating the FXR-FGF15 axis
Hu, N., Qian, M., Liu, Y., Jiang, Z., Xu, C., Zhang, W., & Jiang, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1865237
“Antidiabetic drugs such as metformin and insulin are widely used in managing PTDM, but effective strategies to prevent TAC-induced diabetes mellitus in post-transplant patients are still lacking (Shivaswamy et al., 2016).”
Muongmee, S., Inkong, P., Tasanavipas, P., Pongchaidecha, M., Nadee, C., Mavichak, V., & Rungprai, D. (2026) · Transplantation Direct · doi:10.1097/txd.0000000000001988
Ferreira, H. B., IZZA, L. B., Duarte, A. G., FARIAS, E., YAMASHITA, Y. P., ENSSER, I. R., & Lauria, M. W. (2026) · Research Square · doi:10.21203/rs.3.rs-10453028/v1
Ibraheem, M., Isazade, V., Zhang, N., Katariya, N., Kumar, A., Heilman, R. L., Nair, S. S., Mour, G. K., & Kodali, L. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.09.018
Grabowska, M., & Piasecka, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198501
“Therefore, they should be considered potential indirect mediators of reproductive impairment [76–78].”
Chuang, S.-T., Watts, B., Alcazar, O., & Buchwald, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1947013
“Side effects also include posttransplant diabetes mellitus (PTDM), which can occur in up to 40 – 50% of patients and is largely driven by the immunosuppressive therapy, particularly corticosteroids, calcineurin inhibitors, and mTOR inhibitors (2 – 4).”
Jahromi, M., Gheith, O. A. A., Othman, N. F., Jahrami, K., & Tuomilehto, J. O. (2026) · Research Square · doi:10.21203/rs.3.rs-11258285/v1
Ferreira, H. B., IZZA, L. B., Duarte, A. G., Farias, E. M., WELERSON, A. A., ENSSER, I. R., Yamashita, Y. P. H., & Lauria, M. W. (2026) · Research Square · doi:10.21203/rs.3.rs-11120549/v1
Metadata
- Authors
- Shivaswamy, V., Boerner, B., & Larsen, J.
- Affiliations
- VA Nebraska Western Iowa Health Care System (US)
- University of Nebraska Medical Center (US)
- Corresponding author
- Larsen, Jennifer
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2015-12-09
- Volume
- 37
- Issue
- 1
- Pages
- 37-61
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC4740345
- OpenAlex
- W2190934800
- Cited by
- 328
- References
- 230
- Citations by year
- 2026: 30 · 2025: 36 · 2024: 35 · 2023: 31 · 2022: 32 · 2021: 44 · 2020: 51 · 2019: 29 · 2018: 30 · 2017: 5 · 2016: 4
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- post-transplant diabetes mellitus, solid organ transplantation, immunosuppression, corticosteroids, impaired glucose tolerance, diabetes screening, HbA1c, type 2 diabetes risk factors, drug-drug interactions, hypoglycemia, graft survival, mortality, infection risk, diabetes treatment
- MeSH terms
- Adrenal Cortex Hormones, Animals, Combined Modality Therapy, Diabetes Mellitus, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Postoperative Complications, Risk Factors, Stress, Physiological, Organ Transplantation, Cost of Illness, Practice Guidelines as Topic, Evidence-Based Medicine, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.